c o r r e s p o n d e n c e
To the Editor:
In a recent issue of Nature Medicine, Coury et al. 1 identified a potentially interesting role for interleukin-17 (IL-17A), a proinflammatory cytokine, in the pathogenesis of Langerhans cell histiocytosis (LCH). LCH is a disease characterized by lesions containing CD207 + (langerin + ) histiocytes. However, as shown here, we were unable to identify IL17A gene expression in Langerhans cell lesions, and plasma concentrations of IL-17A did not correlate with disease activity. Therefore, our study does not support a central role for IL-17A in LCH pathogenesis.
The most widely accepted current model of LCH hypothesizes that LCH lesions arise as the result of proliferation of Langerhans cells, dendritic cells normally restricted to skin and lymphatics 2, 3 . However, the etiology of LCH remains speculative. Coury et al. 1 reported expression of IL-17A protein by CD207 + Langerhans cells within LCH lesions as well as highly elevated IL-17A concentrations in serum from individuals with active LCH 1 . IL-17A is a proinflammatory cytokine that initially was thought to be restricted to CD4 + T cells (T helper type 17 cells) and has been described as a major mediator of inflammation, granulopoiesis and immune responses, including granuloma formation. Pathological IL-17A expression has been implicated in autoimmune diseases including rheumatoid arthritis, psoriasis, multiple sclerosis and inflammatory bowel disease 4, 5 . Several studies have evaluated expression of select cytokines within the LCH lesions, primarily by immunohistochemistry, characterizing the lesion microenvironment as a 'cytokine storm' 6 . If the inflammation in LCH were mediated by IL-17A, it would be an attractive target for therapy.
To further define IL-17A expression in LCH lesions, we first analyzed cell-specific IL17A gene expression. We isloated T cells (CD3 + ) and Langerhans cells (CD207 + ) by flow cytometry from 14 fresh LCH biopsy samples, including lesions from individuals with multisystem disease and relapsed disease ( Fig. 1 and Supplementary Table 1 online) . We also processed single-cell suspensions containing all viable cells, from two of the biopsied lesions to determine whether cells within the LCH lesion other than CD3 + or CD207 + cells express IL17A. We used Langerhans cells isolated from foreskin of healthy donors and T cells isolated from tonsils of healthy donors as controls. We extracted the RNA, verified its quality and amplified complementary DNA. We then performed PCR to determine qualitative gene expression (see Supplementary Methods online).
For the LCH lesion and control Langerhans cells, we used 20 ng of amplified template cDNA in PCR reactions with primers for the genes encoding glyceraldehyde 3-phosphate dehydrogenase (GAPDH), secreted phosphoprotein-1 (SPP1) and IL-17A (Fig. 1a) . Uniform expression of GAPDH validated the overall quality of the cDNA template and equal loading. CD207 expression was restricted to normal and LCH lesion Langerhans cells (Fig. 1a) . (Fig. 1a) . For the LCH lesion and control tonsil T cells, we used primers for the GAPDH, CD3E and IL17A genes (Fig. 1b) . In the LCH lesion T cells, IL17A expression was absent or present at extremely low levels, though it was readily detected in control tonsil T cell samples (Fig. 1b) . Therefore, this study is unable to support the observation by Coury et al. 1 that IL-17A is expressed in substantial amounts by Langerhans cells, T cells or any other cells from LCH lesions. The differences between our findings and theirs may be due to the variable specificity of immunohistochemistry compared to PCR. The positive findings in control tonsil T cells suggest that changes in IL17A expression or selective degradation of IL17A message during processing in LCH lesion cells are unlikely to account for the absent IL17A signal in our experiments.
To test the possibility that IL-17A is produced in individuals with LCH by cells outside the LCH lesions, we tested 36 plasma samples from 33 indicates that all viable cells from that lesion were included in the sample. 'CD3' indicates cells with selection specific for CD3 antigen. RNA was isolated from the sorted samples, and then cDNA was generated and specific PCR primers were used to semiquantitatively determine GAPDH (control), CD3E and IL17A expression. a b co r r e s p o n d e n c e from an individual with active juvenile idiopathic arthritis as a positive plasma control (85 pg ml -1 ). Coury et al. 1 identified substantially elevated IL-17A serum concentrations up to 1 ng ml -1 in some individuals with LCH. None of our samples from individuals with active disease, including florid multisystem LCH, had abnormal IL-17A plasma concentrations (0-17 pg ml -1 ). IL17A protein has been detected in healing bone callus in a rat model 9 , so it may be possible some individuals may develop elevated serum concentrations of IL-17A as a result of LCH-associated bone fracture or mechanical bone injury from surgery, although we did not observe this in our subjects with bone lesions. In our study, plasma IL-17A concentration does not correlate with extent or activity of LCH.
In conclusion, IL17A gene expression was undetectable in LCH Langerhans cells from 14 biopsy samples. Furthermore, IL-17A protein was not detected in abnormal amounts in individuals with LCH, including those with severe, active disease. Therefore, this study does not support a central role for IL-17A in the pathogenesis of LCH. 7 . We designated Group 4 to describe individuals with single lesions in all other nonrisk sites. We performed the ELISA experiments at least twice with reagents from two commercially available kits (eBioscience and R&D Systems) with reproducible results. For a positive control, we incubated peripheral blood mononuclear cells isolated from two healthy donors with phorbol myristate acetate (PMA) and ionomycin and sampled the culture medium at 0 h and 48 h. We detected IL-17A detected at predictable concentrations (376-432 pg ml -1 at 48 h) 8 . We also included an unmanipulated sample LCH17  LCH18  LCH19  LCH20  LCH21  LCH22  LCH23  LCH24  LCH25  LCH26  LCH27  LCH28  LCH29  LCH30  LCH31  LCH32  LCH33  LCH34  LCH35  LCH36  LCH37  LCH38  LCH39  LCH40  LCH41  LCH42  LCH43  LCH44  LCH45  LCH46  IL-17A concentration (pg ml - 
Delprat et al. reply:
In our previous report in Nature Medicine 1 , we found interleukin-17A (IL-17A) in samples from humans with active childhood Langerhans cell histiocytosis (LCH) by performing studies at the protein level. We neutralized serum IL-17A activity in biological assays with two antibodies (from either eBiosciences (clone eBio64CAP17) or Dendritics (clone IL512G6.01)) and detected IL-17A by a sandwich ELISA of sera with two other antibodies (developed by Peprotech (kit 900-K84)), by flow cytometry after intracellular staining of monocyte-derived CD1a + CD207 -dendritic cells (DCs), or by confocal immunohistofluorescence, in situ, of LCH lesions with another two antibodies (from R&D Systems (clones 41802 and AF-317-NA)). Allen and McClain 2 did not use these six antibodies.
The absence of IL-17A capture in serum by ELISA in their study 2 may have three explanations. First, we have previously documented an IgG autoimmune response to IL-17A in LCH sera 1 . The capture antibody of the ELISA that we selected, among three tested, was the most efficient to compete with these autoantibodies to capture and detect IL-17A in the serum. Second, IL-17F is 60% homologous to IL-17A and can form heterodimers with intermediate signaling potency 3 . We did not investigate IL-17F expression in LCH, and ELISA kits may differ in their ability to detect IL-17A-IL-17F heterodimers. Finally, it is not easy to detect, in the blood, cytokines whose receptors are ubiquitously expressed. For example, studies have reported contradictory results with respect to the ability to detect serum concentrations of tumor necrosis factor-α (TNF-α) in rheumatoid arthritis 4, 5 , yet TNF-α has a pivotal role in pathogenesis, as illustrated by effective therapy of rheumatoid arthritis with TNF-α inhibitors (adalimumab, infliximab and etanercept).
Consistently with our stated results 1 , Allen and McClain 2 observed that serum concentrations of IL-17A did not correlate with LCH activity, and they found few or no T helper type 17 cells in the LCH lesions.
The absence of IL-17A messenger RNA inside Langerhans cells (LCs), reported by Allen and McClain 2 , may have three explanations. First, in contrast to our approach performed at the protein level in situ, Allen and McClain 2 did not perform their mRNA detection in situ, although the disease-associated microenvironment is responsible for the biological impairment of DCs in LCH 6 . The lifetime of human IL-17A mRNA is unknown, but mRNA lifetimes of cytokines usually range
